Under construction – not a live service
Sign in
Taking people in ItalyNo phase

Gut Bacteria and Leukemia Treatment Response in Chronic Myeloid Leukemia Patients

Studies gut bacteria in adults with chronic myeloid leukemia taking tyrosine kinase inhibitors.

Plain-language title generated from the registry record
Registry title: Interaction Between Gut Microbiota and TKIs in Defining the Clinical Outcomes of Patients With CML

Key facts

Where
Torino, ItalySee the site

Where in Italy

  • AO Ordine Mauriziano di TorinoTorino, ItalyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Carmen Fava
Trial code
NCT06724536
Record updated
9 December 2024
Original description
Gut microbiome (GM) is acquiring increasing importance in human health and disease. GM influences hematopoiesis and immune cells types differentiation. Patients with cancer are characterized by dysbiosis and compromised immunity. In the case of Chronic Myeloid Leukemia (CML), treatment with Tyrosine Kinase Inhibitors (TKIs) restores immunosurveillance; in particular deep molecular response (DMR) is associated with increased levels of NK and CD8+ Tcells. There is no literature on the effects of GM on CML outcomes. This project aims to identify a microbial signature associated with a higher probability of achieving DMR.Read full original descriptionShow less

Interaction Between Gut Microbiota and Tyrosine Kinase Inhibitors in Defining the Clinical Outcomes of Patients With Chronic Myeloid Leukemia

Gut microbiome (GM) is acquiring increasing importance in human health and disease. GM influences hematopoiesis and immune cells types differentiation. Patients with cancer are characterized by dysbiosis and compromised immunity. In the case of Chronic Myeloid Leukemia (CML), treatment with Tyrosine Kinase Inhibitors (TKIs) restores immunosurveillance; in particular deep molecular response (DMR) is associated with increased levels of NK and CD8+ Tcells. There is no literature on the effects of GM on CML outcomes. This project aims to identify a microbial signature associated with a higher probability of achieving DMR.

Inclusion: Age > 18 years old; Chronic Myeloid Leukemia Patients; Any stage of the disease; Exclusioni Criteria:; none.

ClinicalTrials.gov NCT06724536